---

Company Profile - Amgen

One Amgen Center Dr.
Thousand Oaks, CA 91320-1789

Phone: 805-447-1000
Fax: 805-447-1985
Website: http://www.amgen.com
Ticker Symbol: AMGN

Key Facts

Ranked number 57 on Fortune’s 2001 list of the “100 Best Companies to Work For.”
Anti-anemia drug Epogen and immune system booster Neupogen create about 90 percent of Amgen’s revenue.
Key Financial Facts
2001 revenue: $3,763 million
1-yr. growth rate: 9 percent

Personnel Highlights
Number of employees: 7,700
1-yr. growth rate: 5 percent

Company Overview
Amgen stands for Applied Molecular Genetics, a name that succinctly describes the company's mission. The world’s largest biotechnology company, Amgen uses cellular and molecular biology to cure and treat diseases. The company’s primary focus is in cancer, nephrology, inflammation, and neurology/metabolism research.

The company derives 90 percent of its sales—$2.2 billion in 2001—from its immune system duo, Epogen, which combats the anemia that frequently accompanies AIDS, and immune system-stimulator Neupogen. Since September of 2001, Amgen has launched two major new drugs: Neulasta, to treat chemotherapy side effects, and the leukemia therapy drug Aranesp, which it hopes will become a $5 billion per year drug.

Amgen acquired biotech firm Immunex in 2001, opening up additional avenues to explore. The company is busy at work on a new prospect, Enebrel, an arthritis treatment. Amgen is also increasing its manufacturing capacity, with a new plant under construction in Puerto Rico.

Major Line of Business : Biotechnology & Pharmaceuticals

Send additions, corrections, or comments to: exec@3dnet.org.